The failure of Eli Lilly and Co’s Alzheimer’s treatment to slow declines in mental capacity of patients with even mild symptoms cast serious doubt over whether a long-held approach to the memory-robbing disease could provide meaningful benefit to millions of people at risk. Many investors and families had been counting on solanezumab to become the first approved medicine to slow progression of the disease, which the Alzheimer’s Association estimates will strike as many as 28 million Americans by midcentury.
More:
Lilly’s drug for Alzheimer’s fails big trial; shares drop